Please login to the form below

Not currently logged in
Email:
Password:

Cancer Research

This page shows the latest Cancer Research news and features for those working in and with pharma, biotech and healthcare.

Scancell preps phase 2 challenge for melanoma vaccine

Scancell preps phase 2 challenge for melanoma vaccine

Unlike other cancer vaccine technologies ImmunoBodies can target dendritic cells, which means they can generate a broader immune response to tumours, according to Scancell. ... of SCIB2, its second ImmunoBody partnered with Cancer Research UK.

Latest news

  • GSK joins forces with Doudna’s CRISPR lab GSK joins forces with Doudna’s CRISPR lab

    The collaboration consolidates GSK’s focus on genetics, having signed a collaboration consumer genetic testing and research firm 23andMe a year ago. ... A similar long-term partnership in functional genomics was unveiled by AstraZeneca with Cancer

  • Envision appoints new patient partnerships leader

    Joins from Cancer Research UK. Envision Pharma Group is expanding its Envision the Patient team with the appointment of Amanda Boughey, who joins from Cancer Research UK. ... Amanda Boughey. Amanda led multi-stakeholder initiatives at Cancer Research UK,

  • Pfizer poaches cancer R&D head Jeff Settleman from Calico Pfizer poaches cancer R&D head Jeff Settleman from Calico

    Company gaining momentum in oncology. Jeff Settleman is leaving his position as the head of cancer research at Google-backed pharma company Calico Life Sciences, to take up a similar role ... There has never been a more exciting time in cancer research

  • Merck bulks up in cancer with $2.2bn Peloton buy Merck bulks up in cancer with $2.2bn Peloton buy

    VHL is seen in over 90% of cases of clear cell RCC, the most common form of kidney cancer. ... Merck is recognised as a leader in cancer research and shares our commitment to accelerating the development of candidates targeting HIF-2α to help patients

  • Venclexta plus Gazyva approval adds to non-chemo options in CLL Venclexta plus Gazyva approval adds to non-chemo options in CLL

    17%) and peripheral blood (MRD-negativity of 76% vs. 35%). MRD-negativity means no cancer can be detected using a specific and highly sensitive test, defined as less than one CLL ... One such trial is FLAIR, being conducted by Cancer Research UK, which

More from news
Approximately 19 fully matching, plus 339 partially matching documents found.

Latest Intelligence

  • Building Europe’s next breakthrough biotechs Building Europe’s next breakthrough biotechs

    Its founding investors include Cambridge Innovation Capital, Babraham Research Campus through Babraham Bioscience Technologies, Roche's biotech arm Genentech, and Dr Jonathan Milner and Dr Ian Tomlinson, two of the ... life sciences campus in central

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    using a standard search engine to research health worries can do more harm than good. ... She is also a Women of Influence Mentor for Cancer Research UK and a public governor for The Christie NHS Foundation Trust in Manchester and recently took on the

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    The work builds on research at the University of Cambridge that discovered a molecule that reduced the production of Abeta in early-stage tests. ... Yet, as the rapid pace of progress in cancer shows, decades of unsung research into disease biology can

  • Bringing life to precision medicine Bringing life to precision medicine

    Harnessing the power of patient-derived organoids. The global cancer burden. Despite enormous investment over recent decades into research and treatment development, cancer remains one of the leading causes of death ... worldwide, with 18.1 million new

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... A drive to do more. Returning to the theme of cancer research, Galbraith says there is still much more progress to be made –

More from intelligence
Approximately 0 fully matching, plus 33 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical

  • Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

    Under Bahija’s leadership, MedImmune significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic;

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... Association for Cancer Research.

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles. ... cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory

More from appointments
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics